Impact of Gadolinium Injection on MRI Measurements
Assessment of the Impact of Gadolinium Injection on the Measurement of the QSM Signal
Fondation Ophtalmologique Adolphe de Rothschild · NCT04906941
This study is testing how a gadolinium injection during MRI scans affects the accuracy of measurements in patients with white matter disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondation Ophtalmologique Adolphe de Rothschild (network) |
| Locations | 1 site (Paris) |
| Trial ID | NCT04906941 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess how gadolinium injection affects the measurement of quantitative susceptibility mapping (QSM) signals in patients with white matter disease. Participants will undergo MRI scans both with and without gadolinium injection, as part of their standard care, and will complete a questionnaire regarding their previous exposure to gadolinium. The study will help determine the influence of gadolinium on MRI results, which could improve diagnostic accuracy for inflammatory CNS pathologies.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 with inflammatory CNS pathology who require an MRI with gadolinium injection as part of their care.
Not a fit: Patients who are pregnant, breastfeeding, or have had more than three gadolinium MRI exams in their lifetime may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of MRI signal changes due to gadolinium, leading to better diagnostic practices for patients with white matter disease.
How similar studies have performed: While there may be studies assessing gadolinium's effects, this specific approach to measuring QSM signals is novel and not widely tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients over 18 years old * with an inflammatory CNS pathology * to benefit as part of care from an MRI with injection of gadolinium * consent to participate in the study * beneficiary of a social protection scheme Exclusion Criteria: * pregnant or breastfeeding woman * patient benefiting from a legal protection measure * Patient having performed more than 3 MRI exams with gadolinium injection during his life Secondary exclusion criteria : * motion artifact not allowing image interpretation * patient who has not completed one of the following sequences: T1 anatomical, FLAIR, or QSM pre-gadolinium injection. Secondarily excluded patients will be replaced up to a maximum of 25 patients.
Where this trial is running
Paris
- Hhopital fondation adolphe de rothschild — Paris, France (RECRUITING)
Study contacts
- Study coordinator: amélie YAVCHITZ
- Email: ayavchitz@for.paris
- Phone: 0148036454
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: White Matter Disease